Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 77.85 Billion KRW | 8.39% |
| 2022 | 71.83 Billion KRW | 11.71% |
| 2021 | 64.3 Billion KRW | 69.82% |
| 2020 | 37.86 Billion KRW | -19.73% |
| 2019 | 47.17 Billion KRW | -2.44% |
| 2018 | 48.35 Billion KRW | 25.08% |
| 2017 | 38.65 Billion KRW | 17.11% |
| 2016 | 33 Billion KRW | 7.88% |
| 2015 | 30.59 Billion KRW | 2.29% |
| 2014 | 29.91 Billion KRW | 24.69% |
| 2013 | 23.98 Billion KRW | 25.08% |
| 2012 | 19.17 Billion KRW | -9.87% |
| 2011 | 21.27 Billion KRW | -4.31% |
| 2010 | 22.23 Billion KRW | -14.98% |
| 2009 | 26.15 Billion KRW | -36.32% |
| 2008 | 41.07 Billion KRW | -24.5% |
| 2007 | 54.39 Billion KRW | -5.91% |
| 2006 | 57.81 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 70.79 Billion KRW | -9.07% |
| 2024 Q2 | 70.15 Billion KRW | -0.9% |
| 2023 FY | 77.85 Billion KRW | 8.39% |
| 2023 Q3 | 75.78 Billion KRW | -2.22% |
| 2023 Q2 | 77.5 Billion KRW | 2.2% |
| 2023 Q4 | 77.85 Billion KRW | 2.73% |
| 2023 Q1 | 75.83 Billion KRW | 5.58% |
| 2022 Q4 | 71.83 Billion KRW | 7.25% |
| 2022 FY | 71.83 Billion KRW | 11.71% |
| 2022 Q3 | 66.97 Billion KRW | 0.11% |
| 2022 Q2 | 66.89 Billion KRW | -3.36% |
| 2022 Q1 | 69.22 Billion KRW | 7.66% |
| 2021 FY | 64.3 Billion KRW | 69.82% |
| 2021 Q2 | 62.98 Billion KRW | 41.7% |
| 2021 Q3 | 63.54 Billion KRW | 0.89% |
| 2021 Q4 | 64.3 Billion KRW | 1.19% |
| 2021 Q1 | 44.45 Billion KRW | 17.4% |
| 2020 Q2 | 62 Billion KRW | 25.08% |
| 2020 FY | 37.86 Billion KRW | -19.73% |
| 2020 Q3 | 49.02 Billion KRW | -20.94% |
| 2020 Q1 | 49.57 Billion KRW | 5.08% |
| 2020 Q4 | 37.86 Billion KRW | -22.76% |
| 2019 Q4 | 47.17 Billion KRW | 7.39% |
| 2019 Q3 | 43.92 Billion KRW | -5.17% |
| 2019 FY | 47.17 Billion KRW | -2.44% |
| 2019 Q1 | 46.14 Billion KRW | -4.56% |
| 2019 Q2 | 46.32 Billion KRW | 0.37% |
| 2018 Q2 | 57.22 Billion KRW | 35.43% |
| 2018 FY | 48.35 Billion KRW | 25.08% |
| 2018 Q4 | 48.35 Billion KRW | -8.14% |
| 2018 Q3 | 52.63 Billion KRW | -8.01% |
| 2018 Q1 | 42.25 Billion KRW | 0.0% |
| 2017 FY | 38.65 Billion KRW | 17.11% |
| 2017 Q1 | 33 Billion KRW | -14.89% |
| 2017 Q2 | 37.26 Billion KRW | 12.91% |
| 2017 Q3 | 40.61 Billion KRW | 8.99% |
| 2016 Q4 | 38.78 Billion KRW | 20.0% |
| 2016 Q3 | 32.31 Billion KRW | -3.27% |
| 2016 Q2 | 33.41 Billion KRW | 9.2% |
| 2016 Q1 | 30.59 Billion KRW | -1.8% |
| 2016 FY | 33 Billion KRW | 7.88% |
| 2015 Q1 | 29.91 Billion KRW | 67.4% |
| 2015 FY | 30.59 Billion KRW | 2.29% |
| 2015 Q4 | 31.15 Billion KRW | -8.77% |
| 2015 Q3 | 34.15 Billion KRW | -5.54% |
| 2015 Q2 | 36.15 Billion KRW | 20.89% |
| 2014 Q4 | 17.86 Billion KRW | -17.87% |
| 2014 Q3 | 21.75 Billion KRW | -8.65% |
| 2014 Q2 | 23.81 Billion KRW | -0.71% |
| 2014 Q1 | 23.98 Billion KRW | 2.77% |
| 2014 FY | 29.91 Billion KRW | 24.69% |
| 2013 Q3 | 22.38 Billion KRW | 1.44% |
| 2013 Q2 | 22.07 Billion KRW | 15.08% |
| 2013 FY | 23.98 Billion KRW | 25.08% |
| 2013 Q1 | 19.17 Billion KRW | 0.0% |
| 2013 Q4 | 23.34 Billion KRW | 4.26% |
| 2012 FY | 19.17 Billion KRW | -9.87% |
| 2011 Q4 | 16.53 Billion KRW | -6.85% |
| 2011 Q2 | 21.7 Billion KRW | -2.37% |
| 2011 Q3 | 17.75 Billion KRW | -18.21% |
| 2011 Q1 | 22.23 Billion KRW | -2.69% |
| 2011 FY | 21.27 Billion KRW | -4.31% |
| 2010 Q3 | 25.7 Billion KRW | 5.8% |
| 2010 Q2 | 24.29 Billion KRW | -7.11% |
| 2010 Q1 | 26.15 Billion KRW | -12.71% |
| 2010 Q4 | 22.85 Billion KRW | -11.09% |
| 2010 FY | 22.23 Billion KRW | -14.98% |
| 2009 Q4 | 29.96 Billion KRW | -11.77% |
| 2009 Q2 | 39.58 Billion KRW | -3.63% |
| 2009 Q3 | 33.95 Billion KRW | -14.21% |
| 2009 FY | 26.15 Billion KRW | -36.32% |
| 2009 Q1 | 41.07 Billion KRW | -18.08% |
| 2008 Q3 | 50.34 Billion KRW | -4.32% |
| 2008 Q1 | 54.39 Billion KRW | -0.77% |
| 2008 FY | 41.07 Billion KRW | -24.5% |
| 2008 Q4 | 50.13 Billion KRW | -0.43% |
| 2008 Q2 | 52.61 Billion KRW | -3.27% |
| 2007 Q2 | 58.01 Billion KRW | 0.0% |
| 2007 Q4 | 54.82 Billion KRW | -1.13% |
| 2007 Q3 | 55.44 Billion KRW | -4.43% |
| 2007 FY | 54.39 Billion KRW | -5.91% |
| 2006 FY | 57.81 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 91.626% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 88.989% |
| HANDOK Inc. | 449.7 Billion KRW | 82.687% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | 9.119% |
| Yuhan Corporation | 712.33 Billion KRW | 89.07% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 87.679% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -389.842% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 90.86% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -45.451% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 62.182% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -3.574% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 47.32% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -10.592% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -113.682% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 69.0% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 64.723% |
| JW Holdings Corporation | 827.51 Billion KRW | 90.591% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 82.183% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 86.732% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.489% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 1.82% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -11.277% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 67.94% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 76.428% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 84.111% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 90.926% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.489% |
| Yuhan Corporation | 712.33 Billion KRW | 89.07% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 83.705% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 43.156% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 84.931% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 79.489% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 49.618% |
| Korea United Pharm Inc. | 89.96 Billion KRW | 13.458% |
| CKD Bio Corp. | 170.76 Billion KRW | 54.405% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 68.056% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 50.616% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -80.984% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | 1.82% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 87.691% |
| Boryung Corporation | 373.1 Billion KRW | 79.133% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 62.604% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 62.182% |
| JW Lifescience Corporation | 96.44 Billion KRW | 19.271% |